65,437 trials
Medical Overuse · Inappropriate Prescribing · Deprescriptions
Primary: Deprescribing — 748; 653 Participants — p=0.008
Aphasia · Apraxia of Speech
Primary: Percent Syllables Correct — 99.22; 64.26; 99.46; 52.71 percentage — p=0.077
Hematologic Neoplasms · Burns
Primary: Number of Participants Who Experienced an Adverse Event (All Types/Grades) Within a Time Frame up to 24 Hours Following the Transfusion. — 2; 3 Participants
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 64; 7 Participants
Glaucoma · Open Angle Glaucoma
Primary: Performance: Level of Agreement Between GAT and the ARGOS-SC System — -0.3 mmHg
Pitt Hopkins Syndrome
Primary: Safety and Tolerability — 15; 0; 4; 12 Participants
Cochlear Implant
Primary: Monaural Perception for Participants With Cochlear Implants (Arms 1 and 2) Over Time — 18; 10; 40; 34 percent of words correctly repeated — p=0.557
Diet Modification
Primary: Total Energy Expenditure — 2411; 2316; 2318; 2179 kcal/day
HPV Vaccination · Vaccine; Uptake · Vaccination; Series Completion
Primary: Number of Parents Participating in BCT — 8; 10 Participants
Cardiomyopathy · Pregnancy Related
Primary: Left Ventricular Ejection Fraction (LVEF) <50% — 3; 1; 21; 11 Participants — p=0.032
Spinal Cord Injury · Paraplegia · Tetraplegia
Primary: 10meter Walk Test — 46; 48 Participants
Gonorrhea · Chlamydia
Primary: Number of Participants Testing for Gonorrhea and Chlamydia — 390; 361; 12 Participants — p=<0.001
Plagiocephaly, Nonsynostotic
Primary: Change in Cranial Measurements as Measured by CVA — 11.6; 7.1 mm
COVID-19 · COVID-19 Testing
Primary: COVID-19 Testing at Follow-up Assessment — 0.85; 0.61; 0.63; 0.81 proportion of those tested at least once
Refugee Self-reliance · Mental Health Issue · Empowerment
Primary: Change in Self-reliance Index From Baseline to Endline — -0.03; -0.21 score on a scale